
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc. presents a compelling investment opportunity due to its focused pipeline featuring DNTH103, a promising subcutaneous active C1s antibody aimed at treating severe autoimmune and inflammatory diseases. The company has demonstrated progress in its clinical trials, which enhances its differentiation from competitors and supports a positive outlook for future growth. Additionally, a strong cash runway extending into fiscal year 2028, coupled with a recent licensing agreement for DNTH212, positions Dianthus favorably for sustained development and commercialization efforts.
Bears say
Dianthus Therapeutics Inc. faces a challenging financial outlook due to concerns regarding its ability to secure adequate funding, which is essential for advancing its clinical pipeline. The removal of an assumed offering for FY28 and the lowered share count projections for FY25 indicate potential difficulties in financial planning and resource allocation. Without sufficient capital, the company's progress in developing its next-generation complement therapeutics may be significantly hindered, raising concerns about its long-term viability.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares